169 related articles for article (PubMed ID: 10566557)
1. Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53.
Loging WT; Reisman D
Cancer Epidemiol Biomarkers Prev; 1999 Nov; 8(11):1011-6. PubMed ID: 10566557
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53.
Loging WT; Reisman D
Oncogene; 1999 Dec; 18(52):7608-15. PubMed ID: 10602522
[TBL] [Abstract][Full Text] [Related]
3. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
4. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
Thomas S; Reisman D
Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage.
Kawamata H; Omotehara F; Nakashiro K; Uchida D; Shinagawa Y; Tachibana M; Imai Y; Fujimori T
Int J Oncol; 2007 May; 30(5):1089-97. PubMed ID: 17390010
[TBL] [Abstract][Full Text] [Related]
6. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
7. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
[TBL] [Abstract][Full Text] [Related]
8. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.
Mizuarai S; Yamanaka K; Kotani H
Cancer Res; 2006 Jun; 66(12):6319-26. PubMed ID: 16778209
[TBL] [Abstract][Full Text] [Related]
10. The properties of p53 proteins selected for the loss of suppression of transformation.
Olson DC; Levine AJ
Cell Growth Differ; 1994 Jan; 5(1):61-71. PubMed ID: 8123594
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.
Hinds PW; Finlay CA; Quartin RS; Baker SJ; Fearon ER; Vogelstein B; Levine AJ
Cell Growth Differ; 1990 Dec; 1(12):571-80. PubMed ID: 2288874
[TBL] [Abstract][Full Text] [Related]
12. Alterations in mitochondrial and apoptosis-regulating gene expression in photodynamic therapy-resistant variants of HT29 colon carcinoma cells.
Shen XY; Zacal N; Singh G; Rainbow AJ
Photochem Photobiol; 2005; 81(2):306-13. PubMed ID: 15560738
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of genes whose expressions are altered in rat 6 fibroblasts transformed by mutant p53(val135).
Yam JW; Zheng JY; Hsiao WL
Biochem Biophys Res Commun; 1999 Dec; 266(2):472-80. PubMed ID: 10600527
[TBL] [Abstract][Full Text] [Related]
14. Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress.
Li J; Tan J; Zhuang L; Banerjee B; Yang X; Chau JF; Lee PL; Hande MP; Li B; Yu Q
Cancer Res; 2007 Dec; 67(23):11317-26. PubMed ID: 18056458
[TBL] [Abstract][Full Text] [Related]
15. Differential gene expression in apoptosis: identification of ribosomal protein S29 as an apoptotic inducer.
Khanna N; Reddy VG; Tuteja N; Singh N
Biochem Biophys Res Commun; 2000 Oct; 277(2):476-86. PubMed ID: 11032747
[TBL] [Abstract][Full Text] [Related]
16. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain.
Lányi A; Deb D; Seymour RC; Ludes-Meyers JH; Subler MA; Deb S
Oncogene; 1998 Jun; 16(24):3169-76. PubMed ID: 9671396
[TBL] [Abstract][Full Text] [Related]
17. Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study.
Daoud SS; Munson PJ; Reinhold W; Young L; Prabhu VV; Yu Q; LaRose J; Kohn KW; Weinstein JN; Pommier Y
Cancer Res; 2003 Jun; 63(11):2782-93. PubMed ID: 12782583
[TBL] [Abstract][Full Text] [Related]
18. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
[TBL] [Abstract][Full Text] [Related]
19. Inhibition mechanism of a newly cloned candidate tumor suppressor gene JST during hepatocarcinogenesis and its abnormal expression in human hepatocellular carcinoma from Qidong liver cancer risk area, China.
Dong-Dong L; Xi-Ran Z
Hepatogastroenterology; 2004; 51(56):515-25. PubMed ID: 15086194
[TBL] [Abstract][Full Text] [Related]
20. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
Chang FL; Ling YF; Lai MD
Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]